ERBB2 and breast carcinoma: For now, the decision to use anthracycline-based regimens in patients with HER2 positive breast cancer should be carefully weighed, especially in older patients with cardiovascular risk factors, knowing that the added risk of adding such regimens to trastuzumab candidates may rob them of a proven life-prolonging therapy.